Positive results for new HCM drug

22nd May 2020

Last week the US pharmaceutical company MyoKardia announced very promising results from their EXPLORER-HCM clinical trial of the drug Mavacamten, the first drug developed to target the specific molecular defect of obstructive HCM.

The trial confirmed the drug’s ability to relieve obstruction, control symptoms and improve quality of life for people with obstructive HCM. It is hoped that the drug will be made available in the UK in the near future once it has gone through some more testing and the licensing process.

Joel Rose, Chief Executive of Cardiomyopathy UK said “these results are highly impressive, we could be looking at a major breakthrough in the treatment of obstructive HCM, with the real chance of more people with the condition avoiding heart failure and living fuller lives.”